This would give an idea on the value of the company and what it is trying to achieve. Back in January, Lumiradx was to be acquired by a big player in the diagnostics industry Roche. 318Million shares outstanding and a purchase price of $295Million. Annual revenue 2023 of $125MillionUSD.
Roche Purchase
If Febridx and Viradx can produce reasonable revenues over the next few quarters coupled with FFN testing etc, I cant see why they couldn't achieve similar levels.
Ann: Lumos Receives US$400k Phase 1 Milestone from Hologic, page-17
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
-0.004(12.5%) |
Mkt cap ! $13.47M | |||
| Open | High | Low | Value | Volume |
| 3.1¢ | 3.2¢ | 2.8¢ | $59.60K | 1.961M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 419943 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 111769 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| LDX (ASX) Chart |